Cooper Companies Inc
NYSE:COO
Intrinsic Value
The Cooper Cos, Inc. operates as a medical device company. [ Read More ]
The intrinsic value of one COO stock under the Base Case scenario is 55.01 USD. Compared to the current market price of 101.46 USD, Cooper Companies Inc is Overvalued by 46%.
Valuation Backtest
Cooper Companies Inc
Run backtest to discover the historical profit from buying and selling COO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Solid Q1 Results with Optimistic Full Year Guidance
2024-Q1 Earnings Call
The company achieved a strong first quarter with $932 million in revenues, marking a 9% increase from last year. Gross margins rose to 67.3% due to efficiency and pricing strategies, and Non-GAAP EPS surged 18% to $0.85. Despite a modest $5 million in free cash flow due to ongoing capacity expansions, the future looks bright. Revenue expectations have been raised to $3.85 to $3.9 billion for the full year, representing a 7-8% organic increase. CooperVision's revenue guidance is lifted to an 8-9% growth, while CooperSurgical anticipates a 5-7% boost. EPS forecasts are now set at $3.50 to $3.58, a 9-12% improvement from the previous year. The effective tax rate is projected to be about 14.5%, and currency headwinds are expected to have a modest negative impact.
Balance Sheet Decomposition
Cooper Companies Inc
Current Assets | 1.8B |
Cash & Short-Term Investments | 135.2m |
Receivables | 651m |
Other Current Assets | 1B |
Non-Current Assets | 10.2B |
PP&E | 1.7B |
Intangibles | 5.6B |
Other Non-Current Assets | 2.9B |
Current Liabilities | 964.9m |
Accounts Payable | 202.3m |
Accrued Liabilities | 178.7m |
Short-Term Debt | 45.1m |
Other Current Liabilities | 538.8m |
Non-Current Liabilities | 3.4B |
Long-Term Debt | 2.7B |
Other Non-Current Liabilities | 646.4m |
Earnings Waterfall
Cooper Companies Inc
Revenue
|
3.7B
USD
|
Cost of Revenue
|
-1.2B
USD
|
Gross Profit
|
2.4B
USD
|
Operating Expenses
|
-1.9B
USD
|
Operating Income
|
536.7m
USD
|
Other Expenses
|
-245.9m
USD
|
Net Income
|
290.8m
USD
|
Free Cash Flow Analysis
Cooper Companies Inc
What is Free Cash Flow?
COO Profitability Score
Profitability Due Diligence
Cooper Companies Inc's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Cooper Companies Inc's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
COO Solvency Score
Solvency Due Diligence
Cooper Companies Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Score
Cooper Companies Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
COO Price Targets Summary
Cooper Companies Inc
According to Wall Street analysts, the average 1-year price target for COO is 107.67 USD with a low forecast of 94.69 USD and a high forecast of 121.8 USD.
Ownership
COO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
COO Price
Cooper Companies Inc
Average Annual Return | 4.21% |
Standard Deviation of Annual Returns | 17.28% |
Max Drawdown | -45% |
Market Capitalization | 20.2B USD |
Shares Outstanding | 198 756 000 |
Percentage of Shares Shorted | 1.69% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
The Cooper Cos, Inc. operates as a medical device company. The company is headquartered in San Ramon, California and currently employs 12,000 full-time employees. The firm operates through two segments: CooperVision and CooperSurgical. The CooperVision segment is engaged in developing, manufacturing, and marketing a range of products for contact lens wearers, featuring advanced materials and optics. CooperVision designs its products to solve vision challenges such as astigmatism, presbyopia, myopia, ocular dryness, and eye fatigues, with a collection of spherical, toric and multifocal contact lenses. The CooperSurgical segment is focused on advancing the health of women, babies, and families through a diversified portfolio of products and services including medical devices, fertility, diagnostics and contraception. CooperSurgical's products are used in medical office and surgical procedures, primarily by obstetricians/gynecologists (OB/GYN); and fertility products/equipment and genetic testing services used primarily in fertility clinics and laboratories.
Contact
IPO
Employees
Officers
The intrinsic value of one COO stock under the Base Case scenario is 55.01 USD.
Compared to the current market price of 101.46 USD, Cooper Companies Inc is Overvalued by 46%.